Kentucky Medicaid and GLP-1s

What changed, and what the document says

1. Two brand switches a year

   Conditions apply

   A supply-and-cost rule written as a clinical one. It caps how often you can move between products, whatever the reason.

   “NOTE: GLP-1 medications are limited to two brand switches per year.”

   Kentucky Medicaid (MedImpact clinical document) — VERSION: SEPTEMBER 2026

2. Six months at a time

   Conditions apply

   Every approval in the class runs on the same half-year clock.

   “Approval Duration: 6 months”

   Kentucky Medicaid (MedImpact clinical document) — VERSION: SEPTEMBER 2026

3. The exclusion is a footnote, repeated

   Not covered

   It appears under each criteria block rather than once at the top, which is how it survives someone reading only their own drug's page.

   “*Drugs used for anorexia, weight loss, or weight gain are excluded”

   Kentucky Medicaid (MedImpact clinical document) — VERSION: SEPTEMBER 2026

4. A thyroid-cancer history bars the class

   Conditions apply

   Kentucky puts the label's boxed contraindication into the coverage criteria, so it is checked by the payer and not only the prescriber.

   “No personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2”

   Kentucky Medicaid (MedImpact clinical document) — VERSION: SEPTEMBER 2026

5. An A1c that matches the diagnosis

   Conditions apply

   A diagnosis code alone will not do it; the number has to agree with the code.

   “A1c lab value that correlates to a T2DM diagnosis”

   Kentucky Medicaid (MedImpact clinical document) — VERSION: SEPTEMBER 2026

6. No weight-management GLP-1 on the list

   Context

   All 2,300 non-blank lines of the September 2026 drug list were read. Wegovy, Zepbound and Saxenda appear nowhere on it, and neither do the words obesity or weight loss — while the diabetes GLP-1s are all present, which is what proves the scan works.

   “Kentucky Medicaid – Preferred Drug List (PDL)”

   Kentucky Medicaid (MedImpact, the single-PDL pharmacy benefit manager) — September 2026

What the state didn't publish

No GLP-1 approved for weight management appears anywhere on Kentucky's Medicaid drug list, and neither do the words obesity or weight loss.

We checked all 2,300 non-blank lines of the Preferred Drug List dated September 2026, read as text end to end.

Within the same 2,300 lines of the drug list, Ozempic appears 2 times, metformin 17 times, insulin 15 times, and Mounjaro, Trulicity, Victoza, Rybelsus and liraglutide once each. Those lines contain no occurrences of Wegovy, Zepbound, Saxenda, obesity, weight loss, anti-obesity, phentermine or orlistat.

Source: Kentucky Medicaid – Preferred Drug List (PDL), Kentucky Medicaid (MedImpact, the single-PDL pharmacy benefit manager).

Which of these companies serve Kentucky?

Of the 387 companies we grade, 34 publish a list of the states they are licensed in. We checked 251 more and found no such list on any page we read; 102 we have not checked either way.

22 of those lists name Kentucky: Gala Health, Care Bare Rx, Vita Bella, TelePeptide, Levity, Wisp, WePeptideRx, Ways2Well, TeleClinic, Tyde Wellness, Willow, VevaRx, Trimi, Enhance MD, HumeCare+, Rx.com, Mojoon, Peak Wellness, Sprout Health, Allara Health, MEDvidi, and Mixx Health & Wellness. That is a licensure claim each company makes about itself, not something we checked with a state board.

A published list is a starting point, not a guarantee. If availability decides your choice, ask before you pay and get the answer in writing.

Coverage decides what you pay before cash does. See how state Medicaid programs cover GLP-1s and what a prior-authorization denial turns on.